Bortezomib induces canonical nuclear factor-κB activation in multiple myeloma cells

Blood

Volumn 114, Issue 5, 2009, Pages 1046-1052

  Hideshima, Teru ^a   Ikeda, Hiroshi ^a   Chauhan, Dharminder ^a   Okawa, Yutaka ^a   Raje, Noopur ^a   Podar, Klaus ^a   Mitsiades, Constantine ^a   Munshi, Nikhil C ^b   Richardson, Paul G ^a   Carrasco, Ruben D ^a   Anderson, Kenneth C ^a  

^a DANA FARBER CANCER INSTITUTE   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BORTEZOMIB; CASPASE; DNA; I KAPPA B ALPHA; I KAPPA B KINASE; I KAPPA B KINASE INHIBITOR; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; MLN 120B; PROTEASOME INHIBITOR; STRESS ACTIVATED PROTEIN KINASE; TRANSCRIPTION FACTOR RELA; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT; BORONIC ACID DERIVATIVE; I KAPPA B; NF KAPPAB INHIBITOR ALPHA; NF-KAPPAB INHIBITOR ALPHA; PROTEINASE INHIBITOR; PYRAZINE DERIVATIVE; RECEPTOR INTERACTING PROTEIN SERINE THREONINE KINASE 2; RIPK2 PROTEIN, HUMAN; TUMOR PROTEIN;

ARTICLE; CONTROLLED STUDY; CYTOTOXICITY; DNA SYNTHESIS; DOWN REGULATION; DRUG MECHANISM; ENZYME PHOSPHORYLATION; HUMAN; HUMAN CELL; MULTIPLE MYELOMA; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; TUMOR CELL; XENOGRAFT; ANIMAL; DRUG ANTAGONISM; DRUG EFFECT; DRUG SCREENING; ENZYME ACTIVATION; GENE EXPRESSION REGULATION; GENETICS; METABOLISM; MOUSE; MOUSE MUTANT; PHOSPHORYLATION; PHYSIOLOGY; PROTEIN PROCESSING; TUMOR CELL CULTURE;

ANIMALS; ANTINEOPLASTIC AGENTS; BORONIC ACIDS; DOWN-REGULATION; ENZYME ACTIVATION; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; I-KAPPA B KINASE; I-KAPPA B PROTEINS; MICE; MICE, SCID; MULTIPLE MYELOMA; NEOPLASM PROTEINS; NF-KAPPA B; PHOSPHORYLATION; PROTEASE INHIBITORS; PROTEIN PROCESSING, POST-TRANSLATIONAL; PYRAZINES; RECEPTOR-INTERACTING PROTEIN SERINE-THREONINE KINASE 2; TUMOR CELLS, CULTURED; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 70349243697     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2009-01-199604     Document Type: Article

References (41)

1. Ries LAG, Melbert D, Krapcho M, et al, eds. SEER Cancer Statistics Review, 1975-2004. Bethesda, MD: National Cancer Institute; 2007.
2. Hideshima T, Mitsiades C, Tonon G, Richardson PG, Anderson KC. Understanding multiple myeloma pathogenesis in the bone marrow to identify new therapeutic targets. Nat Rev Cancer. 2007;7:585-598.
3. Karin M, Greten FR. NF-κB: linking inflammation and immunity to cancer development and progression. Nat Rev Immunol. 2005;5:749-759. (Pubitemid 41400849)
4. Baldwin AS, Jr. The NF-κB and IκB proteins: new discoveries and insights. Annu Rev Immunol. 1996;14:649-683. (Pubitemid 26130197)
5. Chauhan D, Uchiyama H, Akbarali Y, et al. Multiple myeloma cell adhesion-induced interleukin-6 expression in bone marrow stromal cells involves activation of NF-κB. Blood. 1996;87:1104-1112. (Pubitemid 26043538)
6. Richardson PG, Barlogie B, Berenson J, et al. A phase 2 study of bortezomib in relapsed, refractory myeloma. N Engl J Med. 2003;348:2609-2617. (Pubitemid 36741588)
7. Richardson PG, Sonneveld P, Schuster MW, et al. Bortezomib or high-dose dexamethasone for relapsed multiple myeloma. N Engl J Med. 2005; 352:2487-2498. (Pubitemid 41007864)
8. San Miguel JF, Schlag R, Khuageva NK, et al. Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma. N Engl J Med. 2008;359:906-917.
9. Orlowski RZ, Stinchcombe TE, Mitchell BS, et al. Phase I trial of the proteasome inhibitor PS-341 in patients with refractory hematologic malignancies. J Clin Oncol. 2002;20:4420-4427. (Pubitemid 35334752)
10. Tai YT, Li XF, Breitkreutz I, et al. Role of B-cell-activating factor in adhesion and growth of human multiple myeloma cells in the bone marrow microenvironment. Cancer Res. 2006;66:6675-6682. (Pubitemid 44085624)
11. Hideshima T, Catley L, Yasui H, et al. Perifosine, an oral bioactive novel alkylphospholipid, inhibits Akt and induces in vitro and in vivo cytotoxicity in human multiple myeloma cells. Blood. 2006;107: 4053-4062. (Pubitemid 43726814)
12. Hideshima T, Chauhan D, Richardson P, et al. NF-κB as a therapeutic target in multiple myeloma. J Biol Chem. 2002;277:16639-16647. (Pubitemid 34967682)
13. Wen D, Nong Y, Morgan JG, et al. A selective small molecule IκB kinase β inhibitor blocks nuclear factor κB-mediated inflammatory responses in human fibroblast-like synoviocytes, chondrocytes, and mast cells. J Pharmacol Exp Ther. 2006;317:989-1001. (Pubitemid 43764101)
14. Nagashima K, Sasseville VG, Wen D, et al. Rapid TNFR1-dependent lymphocyte depletion in vivo with a selective chemical inhibitor of IKKβ. Blood. 2006;107:4266-4273. (Pubitemid 43801350)
15. Hideshima T, Neri P, Tassone P, et al. MLN120B, a novel IKKβ inhibitor, blocks multiple myeloma cell growth in vitro and in vivo. Clin Cancer Res. 2006;12:5887-5894. (Pubitemid 44629622)
16. Hideshima T, Mitsiades C, Akiyama M, et al. Molecular mechanisms mediating antimyeloma activity of proteasome inhibitor PS-341. Blood. 2003;101:1530-1534. (Pubitemid 36182530)
17. Carrasco DR, Sukhdeo K, Protopopov M, et al. The differentiation and stress response factor XBP-1 drives multiple myeloma pathogenesis. Cancer Cells. 2007;11:349-360. (Pubitemid 46518314)
18. Hideshima T, Catley L, Raje N, et al. Inhibition of Akt induces significant down-regulation of survivin and cytotoxicity in human multiple myeloma cells. Br J Haematol. 2007;138:783-791. (Pubitemid 47313207)
19. LeBlanc R, Catley LP, Hideshima T, et al. Proteasome inhibitor PS-341 inhibits human myeloma cell growth in vivo and prolongs survival in a murine model. Cancer Res. 2002;62:4996-5000. (Pubitemid 34984425)
20. Chauhan D, Singh A, Brahmandam M, et al. Combination of proteasome inhibitors bortezomib and NPI- 0052 trigger in vivo synergistic cytotoxicity in multiple myeloma. Blood. 2008;111:1654-1664. (Pubitemid 351213457)
21. Jeong SJ, Pise-Masison CA, Radonovich MF, Park HU, Brady JN. A novel NF-κB pathway involving IKKβ and p65/RelA Ser-536 phosphorylation results in p53 inhibition in the absence of NF-κB transcriptional activity. J Biol Chem. 2005; 280:10326-10332.
22. Hideshima T, Richardson P, Chauhan D, et al. The proteasome inhibitor PS-341 inhibits growth, induces apoptosis, and overcomes drug resistance in human multiple myeloma cells. Cancer Res. 2001;61:3071-3076. (Pubitemid 32691956)
23. Hideshima T, Chauhan D, Schlossman RL, Richardson PR, Anderson KC. Role of TNF-α in the pathophysiology of human multiple myeloma: therapeutic applications. Oncogene. 2001;20: 4519-4527. (Pubitemid 32772434)
24. Mitsiades N, Mitsiades CS, Poulaki V, et al. Molecular sequelae of proteasome inhibition in human multiple myeloma cells. Proc Natl Acad Sci U SA. 2002;99:14374-14379. (Pubitemid 35257679)
25. Hideshima T, Chauhan D, Hayashi T, et al. Proteasome inhibitor PS-341 abrogates IL-6 triggered signaling cascades via caspase-dependent down-regulation of gp130 in multiple myeloma. Oncogene. 2003;22:8386-8393. (Pubitemid 37523890)
26. + cells sensitive and resistant to STI571. Blood. 2003; 102:3765-3774.
27. Tai YT, Podar K, Mitsiades N, et al. CD40 induces human multiple myeloma cell migration via phosphatidylinositol 3-kinase/AKT/NF-κB signaling. Blood. 2003;101:2762-2769. (Pubitemid 36857641)
28. von Metzler I, Krebbel H, Hecht M, et al. Bortezomib inhibits human osteoclastogenesis. Leukemia. 2007;21:2025-2034.
29. Burke JR, Pattoli MA, Gregor KR, et al. BMS-345541 is a highly selective inhibitor of I κB kinase that binds at an allosteric site of the enzyme and blocks NF-κB-dependent transcription in mice. J Biol Chem. 2003;278:1450-1456.
30. Karin M, Ben-Neriah Y. Phosphorylation meets ubiquitination: the control of NF-κB activity. Annu Rev Immunol. 2000;18:621-663. (Pubitemid 30365393)
31. Mitsiades CS, Mitsiades N, Poulaki V, et al. Activation of NF-κB and up-regulation of intracellular anti-apoptotic proteins via the IGF-1/Akt signaling in human multiple myeloma cells: therapeutic implications. Oncogene. 2002;21:5673-5683. (Pubitemid 35333000)
32. Annunziata CM, Davis RE, Demchenko Y, et al. Frequent engagement of the classical and alternative NF-κB pathways by diverse genetic abnormalities in multiple myeloma. Cancer Cells. 2007; 12:115-130. (Pubitemid 47199123)
33. Keats JJ, Fonseca R, Chesi M, et al. Promiscuous mutations activate the noncanonical NF-κB pathway in multiple myeloma. Cancer Cells. 2007;12:131-144. (Pubitemid 47208626)
34. Dolcet X, Llobet D, Encinas M, et al. Proteasome inhibitors induce death but activate NF-κB on endometrial carcinoma cell lines and primary culture explants. J Biol Chem. 2006;281:22118-22130. (Pubitemid 44181916)
35. Markovina S, Callander NS, O'Connor SL, et al. Bortezomib-resistant nuclear factor-κB activity in multiple myeloma cells. Mol Cancer Res. 2008;6: 1356-1364.
36. Shumway SD, Miyamoto S. A mechanistic insight into a proteasome- independent constitutive inhibitor κBα (IκBα) degradation and nuclear factor κB (NF-κB) activation pathway in WEHI-231 B-cells. Biochem J. 2004;380:173-180. (Pubitemid 38725742)
37. Chen F, Sun S, Kuhn DC, et al. Involvement of NF-κB in silica-induced cyclooxygenase II gene expression in rat alveolar macrophages. Am J Physiol. 1997;272:779-786. (Pubitemid 27197851)
38. Lin SS, Bassik MC, Suh H, et al. PP2A regulates BCL-2 phosphorylation and proteasome-mediated degradation at the endoplasmic reticulum. J Biol Chem. 2006;281:23003-23012. (Pubitemid 44242330)
39. Chen H, Li M, Campbell RA, et al. Interference with nuclear factor κB and c-Jun NH2-terminal kinase signaling by TRAF6C small interfering RNAinhibits myeloma cell proliferation and enhances apoptosis. Oncogene. 2006;25:6520-6527. (Pubitemid 44607084)
40. Adhikari A, Xu M, Chen ZJ. Ubiquitin-mediated activation of TAK1 and IKK. Oncogene. 2007;26: 3214-3226.
41. Hasegawa M, Fujimoto Y, Lucas PC, et al. A critical role of RICK/RIP2 polyubiquitination in Nodinduced NF-κB activation. EMBO J. 2008;27:373-383. (Pubitemid 351161652)